Clinical trials
Carcinoma, Hepatocellular trials in Belgium
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
83 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2001 | 1 |
| 2002 | 1 |
| 2005 | 1 |
| 2007 | 1 |
| 2008 | 3 |
| 2009 | 3 |
| 2010 | 5 |
| 2011 | 5 |
| 2012 | 4 |
| 2013 | 5 |
| 2014 | 4 |
| 2015 | 3 |
| 2016 | 4 |
| 2017 | 5 |
| 2018 | 4 |
| 2019 | 6 |
| 2020 | 3 |
| 2021 | 8 |
| 2022 | 6 |
| 2023 | 3 |
| 2024 | 1 |
| 2025 | 6 |
| 2026 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 41 |
| Terminated | 15 |
| Recruiting | 14 |
| Active, not recruiting | 8 |
| Unknown status | 4 |
| Withdrawn | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Bayer | 9 |
| Exelixis | 5 |
| Hoffmann-La Roche | 5 |
| University Hospital, Ghent | 5 |
| Bristol-Myers Squibb | 4 |
| Incyte Corporation | 4 |
| Universitaire Ziekenhuizen KU Leuven | 4 |
| Pfizer | 3 |
| Terumo Europe N.V. | 3 |
| AbbVie | 2 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Carcinoma, Hepatocellular | 83 |
| Liver Neoplasms | 15 |
| Neoplasms | 14 |
| Carcinoma, Non-Small-Cell Lung | 13 |
| Colorectal Neoplasms | 10 |
| Squamous Cell Carcinoma of Head and Neck | 9 |
| Carcinoma, Transitional Cell | 8 |
| Ovarian Neoplasms | 8 |
| Small Cell Lung Carcinoma | 7 |
| Triple Negative Breast Neoplasms | 7 |
Trials
Showing 26 to 50 of 83. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.